Achieve Life Sciences Inc. (ACHV)
Summary
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
Achieve Life Sciences NASDAQ: ACHV held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the company's Chief Legal Officer, would act as secretary and record the minutes.
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Achieve Life Sciences Q1 Earnings Call Highlights
Achieve Life Sciences NASDAQ: ACHV used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027.
Achieve Life Sciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 37,760 | $187,667.23 | $236,755.2 | $49,087.97 | 26.16% |
| YA Yinka Akinsola Blue Trust Inc. | 85,888 | $270,547.2 | $538,517.76 | $267,970.56 | 99.05% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 18,000 | $52,920 | $112,860 | $59,940 | 113.27% |
| REF Robert E. Frey Jr. Lakeside Advisors Inc. | 111,101 | $326,636.94 | $696,603.27 | $369,966.33 | 113.27% |
| TK Taro Kuriyama Axq Capita LLP | 15,201 | $44,691 | $95,310.27 | $50,619.27 | 113.27% |
Achieve Life Sciences Inc. (ACHV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Achieve Life Sciences Inc. ever had a stock split?
Achieve Life Sciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard A. Stewart CEO | NASDAQ (CM) Exchange | 004468500 CUSIP |
| US Country | 28 Employees | - Last Dividend | 3 Aug 2017 Last Split | 13 Oct 1995 IPO Date |
Overview
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapeutic solutions for smoking cessation and nicotine addiction. Operating in Canada, the United States, and the United Kingdom, the company focuses on addressing the global smoking health epidemic through its innovative product, cytisinicline. Leveraging license agreements with entities such as Sopharma AD and the University of Bristol, Achieve Life Sciences is committed to providing a scientifically backed, plant-based alternative to nicotine replacement therapies. Based in Vancouver, Canada, the company aims to transform the treatment landscape for individuals looking to overcome nicotine dependency.
Products and Services
- Cytisinicline:
Achieve Life Sciences' flagship product, Cytisinicline, is a plant-based alkaloid with a mechanism of action that focuses on nicotine receptors in the brain. By interacting with these receptors, Cytisinicline aims to alleviate the severity of nicotine withdrawal symptoms, making it a promising therapy for individuals seeking to quit smoking. This innovative approach to smoking cessation underscores the company's dedication to addressing nicotine addiction with alternatives derived from nature, setting a new standard in the therapeutic domain.
